XML 64 R19.htm IDEA: XBRL DOCUMENT

BUSINESS CONCENTRATIONS	12 Months Ended
Dec. 31, 2013
Risks and Uncertainties [Abstract]
BUSINESS CONCENTRATIONS	NOTE 13 - BUSINESS CONCENTRATIONS We purchase our products from several suppliers with approximately 98%, 76%, and 95% of our purchases supplied from one vendor for the years ended December 31, 2013 2012, and 2011, respectively. We sell our prescription dietary supplement products to wholesale distributors, specialty pharmacies, specialty distributors, and chain drug stores that generally sell products to retail pharmacies, hospitals, and other institutional customers. Revenue generated from sales to three customers, Cardinal Health, Inc., Amerisource Bergen, and McKesson Corporation accounted for 79%, 63% and 42% of our recognized revenue for years ended December 31, 2013, 2012, and 2011, respectively. For the years ended December 31, 2013 and 2012, 64% and 28% of our recognized revenue and 97% and 98% of our deferred revenue was generated from sales to only three customers: AmerisourceBergen Corporation, Cardinal Health, Inc., and McKesson Corporation. We did not sell to these customers in prior years.

BUSINESS CONCENTRATIONS

12 Months Ended

Dec. 31, 2013

NOTE 13 - BUSINESS CONCENTRATIONS

We purchase our products from several suppliers with approximately 98%, 76%, and 95% of our purchases supplied from one vendor for the years ended December 31, 2013 2012, and 2011, respectively.

We sell our prescription dietary supplement products to wholesale distributors, specialty pharmacies, specialty distributors, and chain drug stores that generally sell products to retail pharmacies, hospitals, and other institutional customers. Revenue generated from sales to three customers, Cardinal Health, Inc., Amerisource Bergen, and McKesson Corporation accounted for 79%, 63% and 42% of our recognized revenue for years ended December 31, 2013, 2012, and 2011, respectively.

For the years ended December 31, 2013 and 2012, 64% and 28% of our recognized revenue and 97% and 98% of our deferred revenue was generated from sales to only three customers: AmerisourceBergen Corporation, Cardinal Health, Inc., and McKesson Corporation. We did not sell to these customers in prior years.

- Definition

The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.

+ References+ Details